Roivant Officer Files to Sell 7.3M Shares as Citi Lifts PT
Roivant Sciences' president has filed a Form 144 to sell 7.32 million shares, continuing a pattern of insider selling that has totaled $22.31 million since late September. Citigroup's decision to lift
Roivant Officer Files to Sell 7.3M Shares as Citi Lifts PT
NEW YORK, November 1 —
Even as Citigroup projects more than 51% upside for Roivant Sciences Ltd. (ROIV), the company's president has sold $21.66 million in open-market shares across three transactions since late September. A new Form 144 signals an officer proposes to sell 7.32 million more into that same conviction gap.
- Roivant holds $3.84 billion in cash vs. $110 million in debt, more than four years of runway at the current operating burn rate.
- Citigroup raised its ROIV target to $56.00 (~Oct. 29); analyst consensus is $50.00; stock at $36.91.
- Net insider open-market selling: $22.31 million since late September, zero purchases recorded.
Recurring Sales in a Narrow Price Band
Eric Venker (President of Roivant Sciences and CEO of subsidiary Immunovant, which is running IMVT-1402 through trials across six IgG-mediated autoimmune indications including graves' disease and myasthenia gravis) executed three separate open-market blocks between September 30 and October 28. The September 30 tranche combined an option exercise at $3.85 with an immediate same-day sale at $36.62; the October 20 and October 28 blocks followed at prices between $35.09 and $36.59. Combined with Director Melissa Epperly's 17,750-share sale on October 1, total net insider selling reached $22.31 million. The pending Form 144 proposes 7.32 million additional shares, an order of magnitude larger than any single prior block.
The Clinical Case for a $56 Target
The bull thesis rests on two primary programs with large addressable disease areas. Mosliciguat, an inhaled soluble guanylate cyclase activator, targets pulmonary hypertension associated with interstitial lung disease, a condition with limited approved options. IMVT-1402 addresses six IgG-mediated autoimmune indications including graves' disease and sjögren's disease, a category drawing significant pharma capital. Roivant has beaten consensus EPS estimates in each of the past four reported quarters, most recently by 5.6%, and holds $3.84 billion in cash against $110 million in debt, substantial reserves for a company at this clinical stage.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ROIV | $26.7B | n/a | +88.3% |
| IMVT | $6.0B | n/a | +22.7% |
| BBIO | $14.6B | n/a | +20.9% |
| PCVX | $9.8B | n/a | +44.8% |
| LEGN | $4.2B | 20.6x | -32.7% |
| RVMD | $41.0B | n/a | +222.5% |
What the Pipeline Data Has to Answer
Mosliciguat and IMVT-1402 trial results will determine whether Citigroup's $56.00 target, 12% above the analyst consensus of $50.00, reflects pipeline optionality the market has not yet priced or is simply ahead of data still pending. Free cash flow of negative $1.12 billion trailing keeps the dilution question live; any new equity offering at current prices would alter the calculus. The pending Form 144's proposed shares are the immediate market signal to track. Run the free Roivant Sciences Ltd. deep-dive →, or stress-test the discount rate in the DCF calculator.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Is Roivant's president selling shares?
Yes. Roivant Sciences president Eric Venker has filed a Form 144 indicating his intention to sell 7.32 million additional shares. This follows three earlier stock sales totaling $21.66 million between late September and October 28. Including a sale by Director Melissa Epperly, total insider selling has reached $22.31 million with no insider purchases recorded.
What is Citigroup's price target for Roivant?
Citigroup raised its price target for Roivant Sciences to $56.00, representing approximately 51% upside from the current stock price of $36.91, compared to analyst consensus of $50.00. The bull case rests on two primary clinical-stage programs: mosliciguat for pulmonary hypertension associated with interstitial lung disease, and IMVT-1402 addressing six IgG-mediated autoimmune indications.
How much cash does Roivant have?
Roivant Sciences holds $3.84 billion in cash versus $110 million in debt, providing more than four years of operating runway at the company's current burn rate. The company has beaten consensus EPS estimates in each of the past four reported quarters.
What does Roivant Sciences develop?
Roivant Sciences is a clinical-stage biotech company with two primary drug programs: mosliciguat for pulmonary hypertension associated with interstitial lung disease, and IMVT-1402 addressing six IgG-mediated autoimmune indications including graves' disease, myasthenia gravis, and sjögren's disease. The company has substantial financial reserves with $3.84 billion in cash against $110 million in debt.
A Roivant Sciences officer has filed a Form 144 proposing to sell 7.32 million shares, even as Citigroup raised its price target on ROIV to $56.00—more than 51% above the current market price. The move comes on the heels of $21.7 million in open-market share sales by the company's president over the past 30 days, setting up a direct and unresolved conflict between analyst conviction and insider behavior.